Oppenheimer Starts Elite Pharma (ELI) at Buy
More News related to ELI
- Oppenheimer Starts Elite Pharma (ELI) at Buy
- Boenning & Scattergood Starts Elite Pharmaceuticals (ELI) at Market Outperform
- Elite Pharmaceuticals (ELI) Provides Positive Clinical Update
- Elite Pharmaceutical (ELI) and ECR Launch Second Once-Daily Antihistamine
- Elite Pharmaceuticals (ELI) Announces Strategic Alliance with Dr. Veerappan Subramanian
Oppenheimer initiates coverage on Elite Pharma (AMEX: ELI) with a Buy rating and a $4.50 price target.
Related Categories
New CoverageStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
